Figure 1
From: Pharmacological targeting of the β-amyloid precursor protein intracellular domain
CHF5074 lowers AICD nuclear levels in H4swe cells.
(a) Chemical structure of CHF5074. (b) Immunoblot analysis (anti-APP C-terminal antibody) of nuclear extracts from H4swe cells treated for 18 hours with vehicle or with different concentrations of CHF5074 (1–10 μM) as indicated. A single polypeptide band immunoreactive to the anti-APP C-terminal antibody was detected in nuclear templates. Synthetic AICD-59 polypeptide (7 kDa; shown on the right) was used as a molecular mass and electrophoretic mobility reference for these experiments (upper row). Polypeptide band from the same gel was detected with an anti-histone H3 antibody (lower row). Full-length blots were presented in Supplementary Figure S2. Data from multiple experiments are presented as bar plots derived from densitometric quantification of anti-APP C-terminal antibody immunoreactive bands (“test”) normalized with respect to the immunoreactivity signals (“control”) produced by the anti-histone H3 antibody. The test/control ratio for vehicle-treated samples was arbitrarily set to 100%; bars are the mean ± s.e.m. of three independent experiments (*, p < 0.05; ***, p < 0.001).
